Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.

Lars JohanssonPaul D HockingsEva JohnssonNalina DronamrajuJill MaaskeRicardo Garcia-SanchezJohn P H Wilding

Published in: Diabetes, obesity & metabolism (2020)

Dapagliflozin plus saxagliptin significantly decreased liver fat and adipose tissue volume versus glimepiride, and reduced serum liver enzyme levels, indicating a favourable metabolic profile of dapagliflozin plus saxagliptin in patients with type 2 diabetes on metformin therapy.

Keyphrases

adipose tissue
insulin resistance
high fat diet
fatty acid
stem cells
metabolic syndrome
bone marrow
smoking cessation